A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

A new form of tumor infiltrating lymphocyte therapy, a form of personalized cancer immunotherapy, improved the treatment’s ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Mass firings hit U.S. health agencies over the past week, but disruptions to the nation’s medical research system have been ...

A cluster of high-tech plants offering well-paid jobs has transformed Carrigtwohil, quadrupling its population in just two ...

As US President Donald Trump takes aim at the mostly American-owned pharmaceutical factories that dot the Irish countryside, ...